Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* must have metastatic breast cancer~* must have cytologically or pathologically confirmed invasive ductal or lobular carcinoma~* must have measurable or evaluable disease~* ECOG of 0-1~* patients may have received 0, 1. or 2 prior treatments for metastatic breast cancer~* must have adequate organ function~* must be at least 19 years of age~* peripheral neuropathy less than or equal to grade 1~* must have voluntarily signed informed consent~* patients with brain metastases are eligible provided that other measurable disease exists and brain lesions are controlled~Exclusion Criteria:~* patients with other malignancies, except non melanoma of the skin, who have had any evidence of cancer within the last 5 years~* patients with psychiatric illness or other concurrent severe co-morbid medical condition that would preclude study completion~* known uncontrolled existing coagulopathy~* patients with a history of severe hypersensitivity reaction to docetaxel, medications formulated with polysorbate 80 or 5-fluorouracil~* use of other investigational agents in the last 28 days~* pregnant or lactating women~* patients who are known HIV positive~* patients with life expectancy of less than 3 months~* sexually active patients unwilling to practice reliable contraception during the study

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).